Carna Biosciences, Inc. (TYO:4572)
Japan · Delayed Price · Currency is JPY 443.00
-11.00 (-2.42%)
Jun 3, 2026, 3:30 PM JST
Carna Biosciences Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 618.65 | 579 | 636 | 1,625 | 1,386 | 2,017 | |
Revenue Growth (YoY) | 3.33% | -8.96% | -60.86% | 17.24% | -31.28% | 78.02% |
Cost of Revenue | 200.46 | 191 | 171 | 175 | 171 | 135 |
Gross Profit | 418.2 | 388 | 465 | 1,450 | 1,215 | 1,882 |
Selling, General & Admin | 603.91 | 612 | 655 | 664 | 603 | 572 |
Research & Development | 1,851 | 1,851 | 1,886 | 1,903 | 1,882 | 1,841 |
Operating Expenses | 2,455 | 2,463 | 2,541 | 2,567 | 2,485 | 2,413 |
Operating Income | -2,037 | -2,075 | -2,076 | -1,117 | -1,270 | -531 |
Interest Expense | -64.54 | -52 | -3 | -4 | -6 | -4 |
Interest & Investment Income | 1.91 | 5 | 14 | - | - | - |
Currency Exchange Gain (Loss) | -25.97 | -23 | 26 | - | - | 14 |
Other Non Operating Income (Expenses) | -10.92 | -1 | -42 | -5 | -3 | -3 |
EBT Excluding Unusual Items | -2,136 | -2,146 | -2,081 | -1,126 | -1,279 | -524 |
Asset Writedown | -26.86 | -24 | -93 | -4 | -44 | -9 |
Other Unusual Items | -20 | - | - | - | - | - |
Pretax Income | -2,183 | -2,170 | -2,174 | -1,130 | -1,323 | -533 |
Income Tax Expense | 1.85 | 1 | 4 | 22 | 26 | 1 |
Net Income | -2,185 | -2,171 | -2,178 | -1,152 | -1,349 | -534 |
Net Income to Common | -2,185 | -2,171 | -2,178 | -1,152 | -1,349 | -534 |
Shares Outstanding (Basic) | 19 | 19 | 18 | 17 | 14 | 13 |
Shares Outstanding (Diluted) | 19 | 19 | 18 | 17 | 14 | 13 |
Shares Change (YoY) | 3.97% | 6.71% | 6.61% | 23.37% | 7.26% | 3.22% |
EPS (Basic) | -114.23 | -113.60 | -121.61 | -68.57 | -99.06 | -42.06 |
EPS (Diluted) | -114.23 | -113.60 | -121.61 | -68.57 | -99.06 | -42.06 |
Free Cash Flow | - | -2,168 | -1,387 | -1,688 | -834 | -1,577 |
Free Cash Flow Per Share | - | -113.44 | -77.44 | -100.48 | -61.24 | -124.22 |
Gross Margin | 67.60% | 67.01% | 73.11% | 89.23% | 87.66% | 93.31% |
Operating Margin | -329.22% | -358.38% | -326.41% | -68.74% | -91.63% | -26.33% |
Profit Margin | -353.18% | -374.96% | -342.45% | -70.89% | -97.33% | -26.47% |
Free Cash Flow Margin | - | -374.44% | -218.08% | -103.88% | -60.17% | -78.19% |
EBITDA | - | -2,044 | -2,045 | -1,082 | -1,237 | -512 |
EBITDA Margin | - | - | - | -66.59% | -89.25% | -25.38% |
D&A For EBITDA | - | 31 | 31 | 35 | 33 | 19 |
EBIT | -2,037 | -2,075 | -2,076 | -1,117 | -1,270 | -531 |
EBIT Margin | - | - | - | -68.74% | -91.63% | -26.33% |